The complete guide to tirzepatide

What is tirzepatide?

Tirzepatide is a synthetic peptide that activates two incretin hormone receptors simultaneously: GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide). It belongs to a new drug class — dual incretin agonists — and was developed by Eli Lilly. The FDA approved it as Mounjaro for type 2 diabetes in 2022 and as Zepbound for chronic weight management in 2023.

Like semaglutide, tirzepatide is engineered for stability. Its half-life is approximately five days, supporting once-weekly dosing. The molecule is a 39-amino-acid peptide modified with a fatty acid chain that binds to albumin, slowing clearance and extending duration of action.

Brand names that contain tirzepatide

• Mounjaro — once-weekly injection, FDA-approved for type 2 diabetes (max 15 mg).
• Zepbound — once-weekly injection, FDA-approved for chronic weight management (max 15 mg).
• Compounded tirzepatide — prepared by licensed U.S. compounding pharmacies. Same active ingredient; not FDA-reviewed.

The dual GLP-1/GIP mechanism

This is the most important conceptual difference between tirzepatide and every prior weight-loss medication. To understand why dual agonism produces stronger results, it helps to look at each receptor separately.

The GLP-1 component

The GLP-1 effects of tirzepatide mirror those of semaglutide:

• Activates appetite centers in the hypothalamus to reduce hunger and quiet food noise.
• Slows gastric emptying, prolonging fullness after meals.
• Stimulates glucose-dependent insulin release from the pancreas.
• Suppresses glucagon, stabilizing blood sugar between meals.

The GIP component

GIP is the second incretin hormone — historically considered "the other one" because, as a single agonist, GIP did not produce strong weight loss. The breakthrough was discovering that GIP plus GLP-1 synergize:

• Additional appetite suppression. GIP receptors in different brain regions amplify the GLP-1 satiety signal through a parallel pathway.
• Improved insulin sensitivity in adipose tissue. GIP appears to help fat cells handle glucose more efficiently and may improve lipid handling.
• Reduced GI side effects relative to dose. Counterintuitively, the GIP component may slightly buffer the nausea-inducing effects of strong GLP-1 activation, which is part of why tirzepatide is tolerated at higher absolute doses.
• Possible bone-mass and lean-mass benefits. Early evidence suggests GIP signaling preserves bone and muscle better than pure GLP-1 activation, though more research is needed.

Why this matters clinically

Dual agonism does not just produce "more of the same" effect. It recruits a second appetite pathway, which means patients who plateau on a GLP-1 alone often respond to tirzepatide because GIP activates a new lever. This is a recurring real-world finding and a major reason clinicians switch patients to tirzepatide.

What is tirzepatide approved for?

Tirzepatide is also being investigated for non-alcoholic steatohepatitis (NASH/MASH), heart failure with preserved ejection fraction (HFpEF), and chronic kidney disease in obese patients. Off-label use overlaps significantly with semaglutide indications including PCOS and prediabetes.

Who is a candidate for tirzepatide?

The standard FDA criteria for chronic weight management apply.

Standard eligibility (Zepbound criteria)

• Adults with a BMI of 30 or higher, OR
• Adults with a BMI of 27 or higher plus at least one weight-related comorbidity (type 2 diabetes, hypertension, dyslipidemia, obstructive sleep apnea, cardiovascular disease).

Who tirzepatide is not appropriate for

• Personal or family history of medullary thyroid carcinoma (MTC).
• Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
• History of pancreatitis.
• Severe gastrointestinal disease, including gastroparesis.
• Active or recent eating disorder.
• Pregnancy, planned pregnancy, or breastfeeding.
• Type 1 diabetes (tirzepatide is not a substitute for insulin).
• Known hypersensitivity to tirzepatide.

Tirzepatide dosing schedule

Tirzepatide titrates more slowly than semaglutide — a deliberate design choice given its higher absolute dose range. The standard schedule increments by 2.5 mg every four weeks.

Unlike semaglutide, where most patients eventually need 2.4 mg, many tirzepatide patients reach goal weight at 7.5 mg or 10 mg and never need 15 mg. The right dose is the lowest dose that produces durable progress with manageable side effects.

How and where to inject

• Once weekly, on the same day each week.
• Subcutaneous injection — abdomen, upper thigh, or back of upper arm. Rotate sites.
• Time of day does not matter. Take with or without food.
• If you miss a dose: take it within 4 days of your scheduled day. If more than 4 days have passed, skip and resume next scheduled day. Do not double up.

What treatment looks like, week by week

Expected results from tirzepatide

The SURMOUNT trials are the pivotal evidence base for tirzepatide in obesity.

Distribution of response

SURMOUNT-1 reported these category-of-loss numbers at 15 mg: 96% lost ≥5%, 83% lost ≥10%, 63% lost ≥20%, and 36% lost ≥25%. The 25%+ category is roughly the territory of bariatric surgery — historically unreachable with medication alone.

Real-world results

Real-world average is 15–20%, slightly below trial averages for the usual reasons: dose discontinuations, missed weeks, and patients who never reach 15 mg. Patients matching trial results consistently share the habits described in our muscle-preservation guide — adequate protein, resistance training, and sleep.

Side effects of tirzepatide

Side effect profile is similar to semaglutide. The absolute incidence of GI symptoms is comparable, though the higher dose range gives slightly more opportunity for cumulative GI complaints.

Common side effects (>10% of patients)

• Nausea — ~33% in SURMOUNT-1. Usually mild and time-limited.
• Diarrhea — ~22%.
• Constipation — ~17%.
• Vomiting — ~10%.
• Abdominal pain — ~10%.

Less common but notable

• Reflux / heartburn (~6%).
• Fatigue (~7%).
• Injection site reactions (~6%).
• Hair shedding — rapid-loss-related, typically resolves once weight stabilizes.
• Dehydration — secondary to vomiting/diarrhea.

How to minimize side effects

• Eat smaller meals — half your previous portion.
• Prioritize protein. Avoid high-fat or fried foods.
• Hydrate aggressively.
• Add fiber gradually (psyllium, chia).
• Limit alcohol.
• If a dose increase produces severe symptoms, ask your clinician to extend the prior dose for 2–4 more weeks before advancing.

For full strategies, see GLP-1 side effects explained and side effect management.

Serious risks and contraindications

Tirzepatide carries the same boxed warning and serious-event profile as other GLP-1 medications.

Boxed warning: thyroid C-cell tumors

Like semaglutide, tirzepatide carries a boxed warning based on rodent studies. It is contraindicated in anyone with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).

Pancreatitis

Acute pancreatitis has been reported. Severe, persistent abdominal pain radiating to the back requires immediate evaluation.

Gallbladder disease

Rapid weight loss raises gallstone risk. Tirzepatide produces faster loss than semaglutide on average, so the gallbladder risk window may be slightly higher in early treatment.

Acute kidney injury

Usually downstream of dehydration. Stay hydrated; report persistent vomiting.

Hypoglycemia

Low risk in non-diabetic patients. Substantially higher when combined with insulin or sulfonylureas.

Diabetic retinopathy

Rapid glucose improvement may transiently worsen pre-existing retinopathy in diabetic patients. Baseline eye exam recommended.

Pulmonary aspiration during anesthesia

Slowed gastric emptying creates a small but real risk of regurgitation under general anesthesia. Most anesthesiologists now ask patients to hold tirzepatide for one week before elective surgery. Disclose your medication to any surgical or procedural team.

Drug interactions to know

• Insulin and sulfonylureas — combined use raises hypoglycemia risk. Doses often need to be reduced.
• Oral contraceptives — slowed gastric emptying may reduce absorption. Use a backup method for the first 4 weeks of starting and after each dose increase.
• Warfarin — may shift levels via altered absorption. INR monitoring recommended.
• Levothyroxine — recheck TSH 6–8 weeks after starting.
• Alcohol — most patients report dramatically reduced tolerance. Read more →

What happens if you stop tirzepatide

Why weight comes back

Same biology as with semaglutide: ghrelin rebounds, resting metabolic rate stays slightly suppressed (metabolic adaptation), and food noise returns. See why weight keeps coming back.

Maintenance strategies

• Continued full-dose treatment (most durable).
• Reduced maintenance dose — 5 mg or 7.5 mg often holds.
• Sub-therapeutic microdosing in motivated patients with strong lifestyle reinforcement.
• Structured taper plus intensive behavioral support.

Tirzepatide vs semaglutide — head-to-head

The SURMOUNT-5 trial is the only randomized head-to-head comparison published to date. After 72 weeks, tirzepatide produced 20.2% loss versus 13.7% with semaglutide 2.4 mg — an absolute difference of 6.5 percentage points.

For most patients without prior medication trial, both are reasonable first-line options. Tirzepatide produces more weight loss; semaglutide has more long-term cardiovascular outcomes data and a lower cost. Full comparison →

Switching from semaglutide to tirzepatide

This is one of the most common moves in obesity medicine. The triggers:

• Plateau at maximum semaglutide dose (2.4 mg) with weight loss below personal target.
• Suboptimal response — less than 5% loss by 16 weeks at full dose.
• Persistent severe GI side effects on semaglutide (some patients tolerate tirzepatide better, surprisingly).

How the switch is done

There is no formal washout. Most clinicians stop semaglutide on the patient's normal injection day and begin tirzepatide one week later at 2.5 mg, then titrate normally. Some patients experience a brief return of appetite during the transition; this resolves once tirzepatide reaches a therapeutic dose.

Brand-name vs compounded tirzepatide

Compounded tirzepatide became broadly available during the FDA-declared shortage of brand tirzepatide. As of October 2024, the FDA declared the shortage resolved, narrowing the legal pathway for compounding. Patients considering compounded tirzepatide should confirm their telehealth provider works with state-licensed pharmacies and that prescriptions are issued only after a clinician review.

Common misconceptions about tirzepatide

Frequently asked questions

Educational summary

Tirzepatide is a once-weekly injectable that activates both GLP-1 and GIP receptors, producing average weight loss of ~21% at full dose — meaningfully greater than any prior obesity medication. The dual mechanism reduces appetite, slows gastric emptying, improves insulin sensitivity, and quiets food-related thoughts. Side effect profile mirrors semaglutide, with most GI symptoms being mild and time-limited. Stopping the medication produces predictable weight regain, which is why most clinicians treat obesity as a chronic condition warranting long-term maintenance dosing alongside adequate protein and resistance training.

Continue exploring this guide series: